Our Stories

Our Stories

트위터 링크드

07/04/2023 Envisioning Health For All with biosimilars on World Health Day
Envisioning Health For All with biosimilars on World Health Day

This year marks the 75th anniversary of the World Health Organization (WHO). World Health Day aims to celebrate the occasion, while highlighting this year’s theme, “Health For All.” The mission, which strives to tackle global health inequities, is in line with UN SDG’s health-related goals, such as universal health coverage.

WHO defines health inequities as “systematic differences in the health status of different population groups.” Factors such as education, employment status, income level, gender and ethnicity affect one’s health. The role of medicine is paramount in restoring equity in healthcare.  

The coronavirus pandemic further highlighted this reality, as those without sufficient resources were disproportionately impacted. According to a UN report in 2022, the pandemic has led to “significant disruptions in essential health services,” and the costs of healthcare are still threatening the already disadvantaged households. 

Our Contribution to Biosimilars

As we tackle the ongoing impact of global health inequity, biosimilars will continue to play a critical role in shaping the future of healthcare. Samsung Bioepis has continuously expanded into global markets, actively building connections where patients need affordable treatments.

Fueled by our passion for health, Samsung Bioepis envisions a future where biosimilars can play an active role in providing treatment to those who need it the most. Through our expanding pipeline and innovation, we will strive to realize our vision of developing safe and effective medicines. To turn our vision into reality, Samsung Bioepis has released biosimilars in five regions, including Asia, Latin America, Europe, North America and Oceania since our establishment in 2012. Currently, Samsung Bioepis has six biosimilar products that are approved and are available around the world.

Our portfolio reflects our therapeutic focus, including immunology, oncology, ophthalmology, hematology, gastroenterology and endocrinology. Our focus on improving the health of patients will drive every one of our endeavors going forward and out into the world.

Our innovative research and development platforms, combined with manufacturing and partnerships have helped us to establish a global footprint, so we can provide biosimilars to those who need them most. As of January 2023, Samsung Bioepis has provided over 48 million units worldwide1.

Samsung Bioepis emphasizes the importance of ensuring that its products are delivered on time, so that patients can receive treatments at the right time. Hence, supply chain and product continuity are the most important aspects of our mission — it is our promise to our patients that we will deliver the high-quality medicines they need. 

Commitment To Healthcare

Samsung Bioepis will continue to solidify its pipeline and invest in its research capabilities, with the mission of “Health For All” in mind. Progress needs to be made in the research and development efforts of affordable medicine, so that we are a step closer to achieving universal health coverage. On this World Health Day, we hope to continue to engage in conversations that help further integrate biosimilars into healthcare.

1.Data on file. Updated as of Jan 2023

확인 취소
레이어 팝업 닫기